Navigation Links
BioMagnetics Diagnostics Corp. Rated 'Speculative Buy,' Target Price $1.42 by Beacon Equity Research
Date:3/13/2008

DALLAS, March 13 /PRNewswire/ -- BioMagnetics Diagnostics Corp. (Pink Sheets: BMGP) has been rated Speculative Buy with a price target of $1.42 by Beacon Equity Research Analyst, Lisa Springer, CFA.

The full report is available at http://www.BeaconEquity.com.

Anyone interested in receiving alerts regarding BioMagnetics Diagnostics research should email members@beaconequity.com with "BMGP" in the subject line.

In the report, the analyst writes, "Biomagnetics Diagnostics Corp. (BMGP) is a biotechnology company engaged in the discovery, development and marketing of new and innovative diagnostic equipment and immunoassays. The Company, through its wholly owned subsidiary, Bio-Spectrum Technologies, Inc., develops and patents potentially revolutionary diagnostic technologies.

"BMGP's flagship product, the High Throughput Screening-Magnetic Testing Platform (HTS-MTP) diagnostic system, is designed to detect any pathogen -- viral or bacterial -- using any body fluid as the testing median. It is the only system that measures viral load concomitantly with detection. Moreover, using the HTS-MTP system, multiple tests can be performed in one assay in a matter of minutes; that is several hundred percent more assays per hour than existing technologies at a fraction of the cost."

Beacon Equity Research Disclosure

The analysts contributing to this report do not hold any shares of BioMagnetics (BMGP). Additionally the analysts contributing to this report certify that the views expressed herein accurately reflect the analysts' personal views as to the subject securities and issuers. The analyst(s) writing this report recognize and aspire to all of the CFA Institute Guidelines for Independent Research. Beacon Equity Research ("Beacon") certifies that no part of the analysts' compensation was, is, or will be, directly or indirectly, related to the specific recommendation or views expressed by the analysts in the report. Beacon Equity Research and its affiliates have been directly compensated twenty five thousand dollars from a non-controlling third party for enrollment of BMGP in its research program. This report is based on data obtained from sources we believe to be reliable, but is not guaranteed as to accuracy and does not purport to be complete. As such, the report should not be construed as advice designed to meet the particular investment needs of any investor. Any opinions expressed herein are subject to change.

Reuben Sushman of Beacon Equity Research is a member of the National Association of Securities Dealers, CRD number 1755680.

Beacon Equity Research

Jeff Bishop, (469)-252-3505

press@beaconequity.com

http://www.BeaconEquity.com Available Topic Expert(s): For information on the listed expert(s), click appropriate link. JEFF BISHOP http://profnet.prnewswire.com/Subscriber/ExpertProfile.aspx?ei=70781


'/>"/>
SOURCE BeaconEquity.com
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Strategic Diagnostics to Present at Two Upcoming Investor Conferences
2. Strategic Diagnostics Updates Roth Conference Presentation Time
3. Alliance for Medical Devices, Instrumentation and Diagnostics formed between Fraunhofer Center for Manufacturing Innovation and Boston University
4. Rosetta Genomics to Present at the American Association of Cancer Research (AACR) "Molecular Diagnostics in Cancer Therapeutic Development" Conference
5. Indivumed Supports Roche Diagnostics With Immunohistochemistry Services and Clinical Specimens for Biomarker Discovery and Drug Development
6. Quest Diagnostics to Speak at the 2007 UBS Global Life Sciences Conference
7. BoVir(R) Named Best New Veterinary Diagnostics Product in International Animal Pharm Awards
8. Enigma Diagnostics Announces a European Commission Award of EUR3 Million to Fund the Development of a Point of Care Platform for the Rapid Diagnosis of Influenza Infections
9. MedAssets Supply Chain Systems Selects Siemens Medical Solutions Diagnostics for Chemistry, Automation and Immunoassay Solutions
10. Quest Diagnostics Joins National ePrescribing Patient Safety Initiative (NEPSI)
11. Roche Diagnostics Launches CoaguChek XS Plus System to Provide New PT/INR Point-of-Care Solution for Non-Waived Anticoagulation Services
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... , June 24, 2016 Epic ... sensitively detects cancers susceptible to PARP inhibitors by ... tumor cells (CTCs). The new test has already ... therapeutics in multiple cancer types. Over ... DNA damage response pathways, including PARP, ATM, ATR, ...
(Date:6/24/2016)... ... ... Researchers at the Universita Politecnica delle Marche in Ancona combed medical journal articles ... findings are the subject of a new article on the Surviving Mesothelioma website. ... blood, lung fluid or tissue of mesothelioma patients that can help point doctors to ...
(Date:6/23/2016)... ... June 23, 2016 , ... UAS LifeSciences, one of ... their brand, UP4™ Probiotics, into Target stores nationwide. The company, which has been ... Target to its list of well-respected retailers. This list includes such fine stores ...
(Date:6/23/2016)... 23, 2016 /PRNewswire/ - FACIT has announced the ... biotechnology company, Propellon Therapeutics Inc. ("Propellon" or ... of a portfolio of first-in-class WDR5 inhibitors for ... as WDR5 represent an exciting class of therapies, ... medicine for cancer patients. Substantial advances have been ...
Breaking Biology Technology:
(Date:4/28/2016)... First quarter 2016:   , Revenues amounted ... quarter of 2015 The gross margin was 49% (27) ... the operating margin was 40% (-13) Earnings per share ... operations was SEK 249.9 M (21.2) , Outlook   ... M. The operating margin for 2016 is estimated to ...
(Date:4/15/2016)... 2016 Research and Markets has ... Market 2016-2020,"  report to their offering.  , ... ,The global gait biometrics market is expected to ... period 2016-2020. Gait analysis generates multiple ... used to compute factors that are not or ...
(Date:3/29/2016)... , March 29, 2016 LegacyXChange, ... LegacyXChange "LEGX" and SelectaDNA/CSI Protect are pleased to announce ... used in a variety of writing instruments, ensuring athletes ... originally created collectibles from athletes on LegacyXChange will be ... of the DNA. Bill Bollander , ...
Breaking Biology News(10 mins):